Neurol. praxi. 2009;10(2):91-93

New perspectives for botulinum toxin

doc. MUDr. Edvard Ehler CSc
Neurologické oddělení, Krajská nemocnice, Pardubice

Botulinum toxin nowadays represents an important contribution to the treatment of several motor disorders – spasticity, dystonia, hyperkinetic

syndromes, tremor. In a lesser extent botulinum toxin is used in smooth muscle dysfunction (e. g. urine bladder hyperfunctional

syndromes, oesophagus achalazia) and in hyperfuctional autonomic syndromes (e.g. hyperhidrosis, hypersalivation). We suppose that

the therapeutical use of botulinum toxin will include new indications of motor system hyperfunctional syndromes, in visceral disorders,

dysfunctions of autonomic nervous system and new indications in various pain syndromes. In this review article we summarize the most

up-to date indications, mechanisms of action and presumed future development of clinical use of botulinum toxin.

Keywords: botulinum toxin, spasticity, dystonia, autonomic fibers, pain syndromes.

Published: May 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ehler E. New perspectives for botulinum toxin. Neurol. praxi. 2009;10(2):91-93.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Anand KS, Vatss S, Garg J, Sharma S. An open-label trial of botulinum toxin A in treatment of intractable trigeminal neuralgia. Annals of Indian Academy of Neurology 2008; 11 (Suppl): S158-162.
    2. Aoki KR. Future aspects of botulinum neurotoxins. J Neural Transm 2008; 115: 567-573. Go to original source... Go to PubMed...
    3. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, Chia-Ho L, Jenkns S, Turkel C. Intramuscular injection of botulinum toxin for the treatment of wirst and finger spasticity after stroke. N Engl J Med 2002; 347: 395-399. Go to original source... Go to PubMed...
    4. Comella CL, Pullman SL. Botulinum toxins in neurological disease. Muscle Nerve 2004; 29: 628-644. Go to original source... Go to PubMed...
    5. Husárová I, Baláž M, Bareš M. Využitie botulotoxínu v terapii sialorrhei u parkinsonovej choroby. Neurol pro praxi 2007; 3: 168-170.
    6. Jakubowski M, McAllister PJ, Bajwa CH, Ward TN, Smith P, Burstein R. Exploding vs. imploding headache in migraine prophylaxis with botulinum toxin A. Pain 2006; 125: 286-295. Go to original source... Go to PubMed...
    7. Jost WH. Botulinum toxin in painful diseases. Basel: Karger 2003. 173 s. Go to original source...
    8. Kaňovský P. Cervikální dystonie. Cesk Slov Neurol N 2007; 70/103(4): 358-370.
    9. Kaňovský P, Bareš M, Dufek J. Spasticita. Mechanismy, diagnostika a léčba. Praha: Maxdorf 2004. 423 s.
    10. Krhut J, Zachoval R, Hradílek P, Havránek O, Zapletalová O. Botulotoxin v léčbě detruzorové hyperaktivity u pacientů s roztroušenou sklerózou. Cesk Slov Neurol N 2008; 71/104: 429-434.
    11. Millán-Guerrero RO, Isais-Millán S, Bareto-Vizcaíno S, Rivera-Castaňo L, Rios-Madariaga C. Subcutaneous histamine versus botulinum toxin type A in migraine prophylaxis: a randomized, double-blind study. Eur J Neurol 2009; 16: 88-94. Go to original source... Go to PubMed...
    12. Minks E, Bareš M, Husárová I, Ferencová K. Dlouhodobá léčba spasticity dolních a horních končetin botulotoxinem A u dětí s dětskou mozkovou obrnou: retrospektivní studie. Neurol pro praxi 2008; 9(Suppl. C): 3-22.
    13. Moore AP, Ade-Hall RA, Tudur Smith C, Rosenbloom L, Walsh HPJ, Mohamed K, Williamson PR: Two-year placebo-controled trial of botulinum toxin A for leg spasticity in cerebral palsy. Neurology 2008; 71: 122-128. Go to original source... Go to PubMed...
    14. Pérez-Saldaňa MT, Tan EK, Burguera JA. Long-term treatment outcome with different formulations of botulinum toxin. Eur J Neurol 2009; 16: 285-286. Go to original source... Go to PubMed...
    15. Picket A. Diffusion of botulinum toxins: Separating facts from fiction. Botulinum toxin news 2009; 1: 1-2.
    16. Reichel G. Therapy guide spasticity-dystonia.Bremen: Uni-Med Science 2005: 144 s.
    17. Triggs C, Harrington M. Botox confessions. People 2008; 70: 64-68.
    18. Umpiérez ER, Corduente JL. Stroke. Clinical practise guideline. Catalan agency for health technology, assessment and research. Barcelona 2007. B-46. 917-2005.
    19. Ward AB. Spasticity treatment with botulinum toxins. J Neural Transm 2008; 115: 607-616. Go to original source... Go to PubMed...
    20. Ward AB, Molenaers G, Colosimo C, Berardelli A. Clinical value of botulinum toxin in neurological indications. Eur J Neurol 2006; 13 (Suppl. 4): 20-26. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.